Alamar Biosciences raises $219.9M in IPO

Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.

Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.

Positive

• Substantial IPO capital raise: Alamar Biosciences completed an IPO of 12,937,500 shares at $17.00 per share, including the full underwriters’ option, for approximately $219.9 million in aggregate gross proceeds before underwriting discounts and offering expenses.

Negative

• None.

Insights

Equity capital markets analyst

Alamar’s IPO raises about $219.9M and activates its post‑IPO governance structure.

Alamar Biosciences, Inc. completed an IPO of 12,937,500 common shares at $17.00 per share, including 1,687,500 shares from the underwriters’ option. This produced aggregate gross proceeds of approximately $219.9 million before underwriting discounts and offering expenses.

Alongside the IPO closing on April 20, 2026, the company’s amended and restated certificate of incorporation and bylaws became effective, reflecting terms previously approved by the board and stockholders. These documents define Alamar’s public‑company governance structure, which will guide board authority, shareholder rights, and procedural rules.

Overall, this event combines a substantial primary capital raise with the formal transition to a listed, Delaware‑incorporated public company under Nasdaq trading symbol ALMR. Subsequent periodic reports are expected to provide detail on net proceeds after fees and how the new capital is deployed.

8-K Event Classification

3 items: 5.03, 8.01, 9.01

3 items

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

IPO shares sold: 12,937,500 shares Underwriters’ option shares: 1,687,500 shares IPO price: $17.00 per share +2 more

5 metrics

IPO shares sold 12,937,500 shares Aggregate common stock sold in IPO, including underwriters’ option

Underwriters’ option shares 1,687,500 shares Additional shares from full exercise of underwriters’ option

IPO price $17.00 per share Price to the public for each common share in the IPO

Gross IPO proceeds approximately $219.9 million Aggregate gross proceeds before underwriting discounts and expenses

IPO closing date April 20, 2026 Date Alamar Biosciences completed its initial public offering

Key Terms

initial public offering, amended and restated certificate of incorporation, amended and restated bylaws, underwriters’ option, +1 more

5 terms

initial public offering financial

"In connection with the closing of the initial public offering (the “IPO”) of shares of common stock"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

amended and restated certificate of incorporation regulatory

"the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”)"

A company’s amended and restated certificate of incorporation is an updated version of its foundational legal charter that replaces the older document and folds in all changes into one clear copy; it spells out corporate structure, classes of stock, shareholder rights and key governance rules. Investors care because it can change who controls the company, how votes are counted, what claims shareholders have on assets or dividends, and can introduce or remove protections against takeovers—like updating a house title after a major renovation to show who owns what and under what rules.

amended and restated bylaws regulatory

"the Company adopted amended and restated bylaws (the “Restated Bylaws”)"

A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.

underwriters’ option financial

"which includes the exercise in full of the underwriters’ option to purchase an additional 1,687,500 shares"

An underwriters’ option is a provision in a securities offering that lets the group selling the new shares buy a fixed extra amount (often up to 15%) from the issuer after the sale. It acts like a short-term safety valve: if demand is strong, underwriters exercise the option and supply extra shares; if the price falls, they can use the option to stabilize the market. For investors this matters because it affects how many shares come to market, potential short-term dilution, and post-offering price stability—similar to having a reserve supply to smooth out sudden swings.

aggregate gross proceeds financial

"The aggregate gross proceeds from the IPO ... was approximately $219.9 million"

Aggregate gross proceeds are the total amount of money a company expects to receive from a securities offering or financing before any fees, expenses or deductions are taken out. For investors, this number shows the scale of new capital entering the business—like the size of a fuel tank refill—and helps gauge how much cash will be available to pay debts, fund growth or dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alamar Biosciences (ALMR) announce regarding its IPO?

Alamar Biosciences completed its initial public offering of common stock. The company sold 12,937,500 shares, including 1,687,500 from the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in aggregate gross proceeds before underwriting discounts and offering expenses.

How many shares did Alamar Biosciences (ALMR) sell in its IPO and at what price?

Alamar Biosciences sold 12,937,500 common shares at $17.00 each. This total includes 1,687,500 additional shares issued after the underwriters exercised their option in full, resulting in aggregate gross proceeds of about $219.9 million before fees and expenses.

How much money did Alamar Biosciences (ALMR) raise in gross proceeds from the IPO?

The IPO generated approximately $219.9 million in aggregate gross proceeds. This figure is calculated before deducting underwriting discounts, commissions, and estimated offering expenses payable by the company and is based on selling 12,937,500 shares at $17.00 per share.

Did the underwriters exercise their option in the Alamar Biosciences (ALMR) IPO?

Yes, the underwriters’ option was exercised in full. The IPO total of 12,937,500 common shares includes 1,687,500 shares issued pursuant to the full exercise of the underwriters’ option to purchase additional shares at the $17.00 offering price.

What corporate governance changes did Alamar Biosciences (ALMR) implement with its IPO?

Alamar adopted an amended and restated certificate of incorporation and bylaws. These Restated Certificate and Restated Bylaws, previously approved by the board and stockholders, became effective immediately prior to the IPO closing on April 20, 2026, establishing its post‑IPO governance framework.

On which exchange is Alamar Biosciences (ALMR) listed and what is its trading symbol?

Alamar Biosciences’ common stock trades on The Nasdaq Stock Market LLC. The company’s common shares, with a par value of $0.0001 per share, are listed under the trading symbol ALMR following completion of its initial public offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 04:02 PM EDT Learn about SEC filing dates

--12-31 false 0002104204 0002104204 2026-04-20 2026-04-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2026

Alamar Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-43235		36-4899036
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47071 Bayside Parkway

Fremont, CA 94538

(Address of principal executive offices)

Registrant’s telephone number, including area code: (510) 626-9888

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ALMR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Amendment and Restatement of Certificate of Incorporation

In connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Alamar Biosciences, Inc. (the “Company”) on April 20, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.

Amendment and Restatement of Bylaws

Effective as of April 20, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Board and stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO.

The foregoing descriptions of the Restated Certificate and Restated Bylaws are qualified in their entirety by reference to the full text of the Restated Certificate and Restated Bylaws, which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated herein by reference.

Item 8.01 Other Events

On April 20, 2026, the Company completed its IPO of an aggregate of 12,937,500 shares of common stock (which includes the exercise in full of the underwriters’ option to purchase an additional 1,687,500 shares of common stock) at a price to the public of $17.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, was approximately $219.9 million.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1		Amended and Restated Certificate of Incorporation of the Registrant.
3.2		Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-294697), filed with the Commission on April 13, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Alamar Biosciences, Inc.
By:		/s/ Yuling Luo
		Yuling Luo
		Chief Executive Officer

Dated: April 20, 2026

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-3.1 EX-3.1 29.7 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.5 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB